Q32 Bio (QTTB) Operating Expenses (2017 - 2026)
Q32 Bio (QTTB) posted quarterly Operating Expenses of $7.7 million for Q1 2026, down 36.85% year-over-year from $12.2 million in Q1 2025, and down 1.73% quarter-over-quarter from $7.9 million in Q4 2025.
Q32 Bio (QTTB) Operating Expenses (2017 - 2026) Analysis & Trends
Q32 Bio's Operating Expenses history runs 10 years deep, the most recent figure standing at $7.7 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 36.85% year-over-year to $7.7 million; the TTM figure through Mar 2026 stood at $32.3 million (down 49.08% YoY), while the FY2025 annual figure was $36.8 million, down 44.28% from the prior year.
- Operating Expenses for Q1 2026 stood at $7.7 million, down from $7.9 million in the prior quarter.
- The five-year high for Operating Expenses was $38.4 million in Q1 2022, with the low at $7.6 million in Q3 2025.
- The 5-year median for Operating Expenses is $12.2 million (2025), against an average of $17.0 million.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses plunged 73.14% in 2023, then jumped 94.82% in 2024.
- Q32 Bio's Operating Expenses stood at $35.3 million in 2022, then plunged by 68.42% to $11.1 million in 2023, then jumped by 30.31% to $14.5 million in 2024, then slumped by 45.9% to $7.9 million in 2025, then fell by 1.73% to $7.7 million in 2026.
- Business Quant data shows QTTB's Operating Expenses at $7.7 million in Q1 2026, $7.9 million in Q4 2025, and $7.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Q32 Bio | 359.61 Mn | 253.31 Mn | - | 9.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.12 Mn |
| Mar 31, 2026 | 7.72 Mn |
| Dec 31, 2025 | 7.86 Mn |
| Sep 30, 2025 | 7.58 Mn |
| Jun 30, 2025 | 9.17 Mn |
| Mar 31, 2025 | 12.23 Mn |
| Dec 31, 2024 | 14.53 Mn |
| Sep 30, 2024 | 18.81 Mn |
| Jun 30, 2024 | 17.92 Mn |
| Mar 31, 2024 | 14.84 Mn |
| Dec 31, 2023 | 11.15 Mn |
| Sep 30, 2023 | 9.66 Mn |
| Jun 30, 2023 | 10.48 Mn |
| Mar 31, 2023 | 10.32 Mn |
| Dec 31, 2022 | 35.30 Mn |
| Sep 30, 2022 | 33.66 Mn |
| Jun 30, 2022 | 29.11 Mn |
| Mar 31, 2022 | 38.42 Mn |
| Dec 31, 2021 | 34.43 Mn |
| Sep 30, 2021 | 32.34 Mn |